Summary & Overview
HCPCS Level II J9277: Pembrolizumab with Berahyaluronidase Injection, 1 mg
HCPCS Level II code J9277 designates an injection of pembrolizumab, reported per 1 mg, in combination with berahyaluronidase alfa-pmph. This entry captures billing for an oncology biologic formulation that pairs the immune checkpoint inhibitor pembrolizumab with a recombinant hyaluronidase to facilitate subcutaneous or other enhanced delivery. Nationally, accurate coding for high-cost oncology biologics is essential for claims processing, utilization tracking, and ensuring consistent clinical documentation.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for use of pembrolizumab with hyaluronidase, the typical sites where the service is provided (outpatient oncology clinics and hospital outpatient infusion centers), and what to expect from billing lines that use this HCPCS code. The publication summarizes coding conventions, common reimbursement considerations, and related billing practice implications for hospital and physician outpatient settings. Data elements not provided in the source input are identified as unavailable; the content focuses on the code’s purpose, service setting, and payer scope rather than proprietary benchmarking or state-level policy specifics.
Billing Code Overview
HCPCS Level II code J9277 describes an injection of pembrolizumab, 1 mg, combined with berahyaluronidase alfa-pmph. This code represents the drug administration entry for the active agent pembrolizumab measured per milligram alongside the specified recombinant hyaluronidase component.
Service type: Drug administration / oncology biologic therapy
Typical site of service: Outpatient oncology clinic or hospital outpatient infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an FDA-approved malignancy (for example, metastatic non-small cell lung cancer or recurrent/metastatic head and neck squamous cell carcinoma) who is scheduled to receive an infusion of the monoclonal anti–PD-1 antibody pembrolizumab combined in the same clinical encounter with administration of berahyaluronidase alfa-pmph to facilitate subcutaneous dispersion of coadministered agents. The clinical workflow begins with an oncology clinic visit for treatment planning and review of prior response and laboratory results. Pre-infusion nursing assessment includes verification of the signed consent, allergy check, vital signs, weight-based dose calculation, and review of recent laboratory values (including liver function and complete blood count). The pharmacy compounds the dose of J9277 as ordered. On the day of service, the patient is brought to the infusion suite or oncology clinic treatment room; nursing confirms patient identity, performs a focused assessment, establishes venous access or prepares the subcutaneous site as appropriate, and administers pembrolizumab with berahyaluronidase alfa-pmph according to approved dosing and institutional protocol. The nurse monitors for infusion- or injection-related reactions during and after administration, documents lot numbers and administration details, and provides post-treatment instructions. Billing occurs under HCPCS Level II code J9277 for the drug administration event, with appropriate modifiers applied when indicated and the associated diagnosis code(s) reported for medical necessity and reimbursement purposes.
Coding Specifications
| Modifier | Description | When to Use |
|---|